Sensei Biotherapeutics, INC

Faeth Therapeutics announced its second quarter 2026 financial results, detailing progress in its PIKTOR clinical trials for endometrial and breast cancer, alongside a substantial increase in cash reserves.

Faeth Therapeutics announced performance-based stock option grants to employees, tied to a $70 stock price hurdle.

Faeth Therapeutics, Inc. has entered into a Sales Agreement to offer and sell up to $150 million of its common stock through TD Securities (USA) LLC.

Sensei Biotherapeutics, Inc. has officially changed its name to Faeth Therapeutics, Inc., effective June 15, 2026, and appointed Anand Parikh as its new President and CEO, alongside other leadership and board changes.

Sensei Biotherapeutics stockholders approved new equity incentive and employee stock purchase plans and authorized a significant increase in common stock.

Sensei Biotherapeutics files pro forma financial data ahead of the June 10, 2026, shareholder vote on Series B Preferred Stock conversion.

Faeth Therapeutics announced its Q2 2026 financial results, detailing a significant increase in operating expenses and net loss following the acquisition of Faeth Therapeutics and a concurrent private placement.

Sensei Biotherapeutics announces significant increase in operating expenses and net loss for Q1 2026, primarily due to the acquisition of Faeth Therapeutics and associated costs.

Sensei Biotherapeutics discontinues its lead therapeutic candidate, solnerstotug, implements a 65% workforce reduction, and explores strategic alternatives including a potential wind-down, raising substantial doubt about its ability to continue as a going concern.

Sensei Biotherapeutics reported reduced operating losses and extended its cash runway into Q2 2026 by pausing preclinical programs and focusing on its lead cancer therapeutic, solnerstotug, despite ongoing going concern doubts.

Sensei Biotherapeutics announces its Q1 2025 financial results, highlighting a net loss of $6.9 million and expressing substantial doubt about its ability to continue as a going concern without additional financing.

Sensei Biotherapeutics reports Q3 2024 results, announces a strategic realignment to focus on SNS-101, and extends its cash runway into Q2 2026.

Sensei Biotherapeutics files an amendment to its 2025 10-K report, primarily to update Item 1. Business section and include revised Section 302 certifications.

Sensei BioTherapeutics streamlines operations to prioritize clinical development of solnerstotug, extending its financial runway into the second quarter of 2026.

Sensei Biotherapeutics reports its 2023 financial results, highlighting progress in its clinical pipeline and extending its cash runway into the fourth quarter of 2025.

Faeth Therapeutics, Inc. reports that Chief Financial Officer Brian C. Stephenson acquired a significant number of company shares across multiple transactions in late June and early July 2026.

Faeth Therapeutics, Inc. Chief Financial Officer, Brian C. Stephenson, reported the purchase of common stock on June 24th and June 26th, 2026.

Faeth Therapeutics, Inc. reports that Chief Financial Officer Brian C. Stephenson acquired a significant number of company shares across multiple transactions on June 22nd and 23rd, 2026.

Faeth Therapeutics, Inc. reports that President and CEO Anand Kiran Parikh acquired common stock through option exercises and purchases.

Director Saira Ramasastry was granted 25,000 stock options in Sensei Biotherapeutics, Inc. as part of a standard equity compensation plan.

CEO Anand Kiran Parikh converted Series B Preferred Stock into 761,428 shares of common stock following a merger.

Sensei Biotherapeutics seeks stockholder approval for post-acquisition governance, share authorization, and equity plans following its merger with Faeth Therapeutics.

Sensei Biotherapeutics has filed a definitive proxy statement with the SEC.

Sensei Biotherapeutics is seeking stockholder approval for a reverse stock split to increase its stock price and maintain its Nasdaq listing.

Sensei Biotherapeutics will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the selection of Deloitte & Touche LLP as its independent accounting firm.

Sensei Biotherapeutics will hold its annual stockholders meeting virtually on June 11, 2024, to elect directors and ratify the selection of its independent accounting firm.

Millennium Management LLC and affiliated entities have reported beneficial ownership of 3.1% of Sensei Biotherapeutics, Inc. common stock as of June 1, 2026.

Millennium Management and affiliated entities have filed a Schedule 13G reporting a 9.6% beneficial ownership stake in Sensei Biotherapeutics, Inc.

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed a Schedule 13G, reporting beneficial ownership of 132,873 shares, representing 9.9% of Sensei Biotherapeutics, Inc. common stock.

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 9.40% in Sensei Biotherapeutics, Inc., as of March 31, 2026.

Trails Edge Capital Partners, LP, along with its affiliates, has disclosed a 9.9% beneficial ownership stake in Sensei Biotherapeutics, Inc. through a Schedule 13G filing.